Exploring The Potential of GLC11 as A Drug Target and Biomarker

Target Name: SIGLEC11

NCBI ID: G114132

SIGLEC11

Exploring The Potential of GLC11 as A Drug Target and Biomarker

Sialic acid-binding Ig-like lectin 11 (ISOFORM 1), also known as GLC11, is a type of carbohydrate-binding protein that is expressed in many different tissues throughout the body. It is characterized by its ability to recognize and bind to sialic acid, which is a type of carbohydrate found on the surface of many different cell types.

GLC11 is a member of the Ig-like lectin family, which includes proteins that are able to recognize and bind to a wide variety of carbohydrates. These proteins are often involved in the immune system, and they have been implicated in a number of different diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the reasons why GLC11 is of interest as a potential drug target is its ability to interact with the immune system in a way that can be exploited to treat a variety of different conditions. For example, GLC11 has been shown to play a role in the development and progression of cancer, and it has been shown to be involved in the development of neurodegenerative diseases.

In addition to its potential as a drug target, GLC11 is also of interest as a biomarker. Because it is expressed in many different tissues throughout the body, it can be used as a marker for a variety of different diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it an attractive candidate for use as a diagnostic tool, as well as a target for drug development.

GLC11 is also of interest as a potential therapeutic target because it is able to interact with a variety of different carbohydrates, rather than just one type of carbohydrate. This makes it more versatile and less dependent on specificcarbohydrates for its function. This may make it an attractive candidate for use as a therapy for a variety of different conditions.

Overall, GLC11 is a fascinating protein that has the potential to be a drug target and a biomarker. Its ability to interact with the immune system and a variety of different carbohydrates makes it an attractive candidate for both these roles. Further research is needed to fully understand the full potential of GLC11 and its potential as a therapy.

Protein Name: Sialic Acid Binding Ig Like Lectin 11

Functions: Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,8-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules

The "SIGLEC11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLEC11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets